Inzoomen: druk op uw toetsenbord op CtrlCommand + +
Uitzoomen: druk op uw toetsenbord op CtrlCommand + -
Gebruik knijpzoomen om eenvoudig in en uit te zoomen

RASFX study

Laatste wijziging: 24 januari 2022

Potential prognostic factors, early detection and long-term monitoring of joint damage in a cohort of 350 rheumatoid arthritis or psoriatic arthritis patients using high resolution X-rays, bone-, cartilage- and inflammation-related biomarkers and auto-antibody screening

 

Principal Investigator: Prof. Dr. Veerle Somers

 

A 3 year follow-up of a cohort of 350 patients with rheumatoid arthritis (RA) or psoriatic arthritis (PSA) for the presence and progression of joint damage, including erosions.

 

It is a strictly observational protocol in which patients will be prospectively followed for a 5 year period both by conventional X-ray and small focus X-ray (SFX). When blood drawn take place in the context of clinical diagnosis and follow-up we will measure bone, cartilage and inflammation biomarkers and auto-antibodies.

This long-term follow-up will allow us to validate the use of SFX for early detection of erosions in RA and PsA patients.

 

We will in addition explore to what degree biomarkers can be used as surrogate markers for the development of erosion and progression of joint damage. The analysis will include a stratification by treatment.

Eventually the study will allow to identify auto-antibodies that could be used as prognostic marker for disease progression and joint damage.
This study entails a 3-year follow up of 350 patients with rheumatic (RA) and psoriatic arthritis (PsA), researchin the presence and progression of joint damage, including wear and tear.